Dec. 15 at 1:51 AM
$CNSP Berubicin: The way I see it, median overall survival was short in both arms and essentially a statistical tie with about 90% of the trial population represented in the March, 2025 data read. With the on-going planned extra year of analysis, it is still possible a “tail” of long‑term survivors could influence final OS comparisons in addition to including the remaining 10% population in the analysis plus any perspective guidance from sub-groups. This could either substantiate the OS null read back in March, take it to clear negativity or the possibility of influence of a “tail” of more mature trial survival data actually modifying the conclusion to positive due to late‑survival separation, etc. Current estimated primary end date of the study is 2/1/26, a mere 6 weeks to go to lock up the data and then conclude the study estimated as 3/31/2026. We don’t know what the final outcome at this point but we’re clearly in the red-zone. The above is my opinion and not investment advice.
